0.5512
News
Price History
Option Chain
Financials
Insider Trading
Why CFRX Down?
Discussions
Forecast
Stock Split
Dividend History
Contrafect Corporation Stock (CFRX) Latest News
GlobeNewswire Inc.
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

Benzinga
Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
GlobeNewswire Inc.
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
GlobeNewswire Inc.
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023

Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga
Why Kosmos Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
GlobeNewswire Inc.
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
PennyStocks
Top Penny Stocks Trading Mistakes to Avoid
PennyStocks
Penny Stocks Trading and Options: Strategies for Leveraged Profits
Benzinga
Why American Software Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Why Sientra Shares Are Trading Higher By 84%; Here Are 20 Stocks Moving Premarket
GlobeNewswire Inc.
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023
PennyStocks
Discover the Top Penny Stock Technical Indicators By Effectiveness
Benzinga
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Nevro Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
About Contrafect Corporation
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
Cap:
|
Volume (24h):